Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 7/20 | 0.39 |
| ▸ | JAK3 | P52333 | 7/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3241923 | 0.92 | MAPT (0.53) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3249037 | 0.89 | ALOX5 (0.43) | ALDH1A1MAPTMEN1KMT2ADHODH | |
| SCHEMBL3253176 | 0.89 | MEN1 (0.44) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3253478 | 0.88 | CSNK2A2 (0.41) | MAPTPARP1GAA | |
| SCHEMBL3253872 | 0.88 | PARP1 (0.41) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3254695 | 0.85 | ABL1 (0.46) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3251297 | 0.85 | MEN1 (0.43) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3251009 | 0.84 | PARP1 (0.47) | MAPTJAK2JAK3SMN1; SMN2PARP1 | |
| SCHEMBL3249681 | 0.83 | PARP1 (0.44) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL3249830 | 0.82 | CDK5 (0.49) | ALDH1A1MAPTMEN1KMT2AJAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899335-B1 | PYRROLOQUINOLINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | PF MEDICAMENT (FR) | 2010-05-19 | — | — | EP | claimed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-8426437-B2 | Pyrroloquinoline derivatives and their use as protein kinases inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | PIERRE FABRE MEDICAMENT (FR) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042876-A1 | Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors | MAP3K1, MAP3K2, MAP3K7 | ALDH1A1 3830/4885MAPT 734/4885MEN1 3749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.